

# Viji Shridhar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1068155/publications.pdf>

Version: 2024-02-01

77  
papers

4,878  
citations

101543

36  
h-index

95266

68  
g-index

80  
all docs

80  
docs citations

80  
times ranked

6970  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting LRRCL15 Inhibits Metastatic Dissemination of Ovarian Cancer. <i>Cancer Research</i> , 2022, 82, 1038-1054.	0.9	26
2	Exploiting LRRCL15 as a Novel Therapeutic Target in Cancer. <i>Cancer Research</i> , 2022, 82, 1675-1681.	0.9	12
3	PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma. <i>Oncogene</i> , 2022, 41, 4003-4017.	5.9	20
4	Repurposing quinacrine for treatment-refractory cancer. <i>Seminars in Cancer Biology</i> , 2021, 68, 21-30.	9.6	52
5	Quinacrine-Induced Autophagy in Ovarian Cancer Triggers Cathepsin-L Mediated Lysosomal/Mitochondrial Membrane Permeabilization and Cell Death. <i>Cancers</i> , 2021, 13, 2004.	3.7	19
6	Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 182.	8.6	18
7	Quinacrine Induces Nucleolar Stress in Treatment-Refractory Ovarian Cancer Cell Lines. <i>Cancers</i> , 2021, 13, 4645.	3.7	7
8	Quinacrine Has Preferential Anticancer Effects on Mesothelioma Cells With Inactivating NF2 Mutations. <i>Frontiers in Pharmacology</i> , 2021, 12, 750352.	3.5	4
9	Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer. <i>Oncogene</i> , 2021, 40, 1409-1424.	5.9	27
10	Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 682-688.	1.4	20
11	Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection. <i>Gynecologic Oncology</i> , 2020, 156, 387-392.	1.4	22
12	Signals from the Metastatic Niche Regulate Early and Advanced Ovarian Cancer Metastasis through miR-4454 Downregulation. <i>Molecular Cancer Research</i> , 2020, 18, 1202-1217.	3.4	15
13	Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer. <i>Biochemical Pharmacology</i> , 2020, 178, 114003.	4.4	10
14	Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. <i>Journal of Clinical Oncology</i> , 2020, 38, 6072-6072.	1.6	0
15	Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 986.	2.8	7
16	PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses. <i>Cell Death and Disease</i> , 2019, 10, 725.	6.3	31
17	Genes associated with bowel metastases in ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 495-504.	1.4	40
18	Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. <i>International Journal of Cancer</i> , 2019, 144, 178-189.	5.1	103

#	ARTICLE	IF	CITATIONS
19	Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 2487.	3.3	51
20	Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 58.	2.8	7
21	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 3794-3801.	7.0	103
22	Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer. <i>Scientific Reports</i> , 2017, 7, 41977.	3.3	15
23	Quinacrine in endometrial cancer: Repurposing an old antimalarial drug. <i>Gynecologic Oncology</i> , 2017, 146, 187-195.	1.4	24
24	Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2016, 114, 1412-1420.	6.4	8
25	AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage- $\text{Th}17$ Axis. <i>Journal of Immunology</i> , 2016, 197, 747-760.	0.8	25
26	<i>TP53</i> mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. <i>Nucleic Acids Research</i> , 2015, 43, 6945-6958.	14.5	46
27	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. <i>Gynecologic Oncology</i> , 2015, 137, 14-22.	1.4	79
28	PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. <i>European Journal of Cancer</i> , 2015, 51, 879-892.	2.8	53
29	The heparan sulfate mimetic PG545 interferes with Wnt/ $\beta$ -catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. <i>Oncotarget</i> , 2015, 6, 4992-5004.	1.8	43
30	Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. <i>Oncotarget</i> , 2015, 6, 23548-23560.	1.8	35
31	HSulf-1 deficiency dictates a metabolic reprogramming of glycolysis and TCA cycle in ovarian cancer. <i>Oncotarget</i> , 2015, 6, 33705-33719.	1.8	28
32	Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth. <i>Oncotarget</i> , 2015, 6, 36354-36369.	1.8	58
33	Preclinical Therapeutic Potential of a Nitrosylating Agent in the Treatment of Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e97897.	2.5	20
34	Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. <i>Oncotarget</i> , 2014, 5, 11365-11380.	1.8	37
35	The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics. <i>Frontiers in Oncology</i> , 2014, 4, 195.	2.8	163
36	The Wilms' Tumor Gene WT1 $\Delta$ 17AA $\Delta$ KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model. <i>Translational Oncology</i> , 2014, 7, 580-589.	3.7	8

#	ARTICLE	IF	CITATIONS
37	Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. <i>International Journal of Cancer</i> , 2014, 135, 1783-1789.	5.1	13
38	Non-metastatic 2 (NME2)-mediated suppression of lung cancer metastasis involves transcriptional regulation of key cell adhesion factor vinculin. <i>Nucleic Acids Research</i> , 2014, 42, 11589-11600.	14.5	47
39	Tumor Hypomethylation at 6p21.3 Associates with Longer Time to Recurrence of High-Grade Serous Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3084-3091.	0.9	32
40	Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer. <i>Cancer &amp; Metabolism</i> , 2014, 2, 13.	5.0	27
41	Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5509-5509.	1.6	16
42	Metformin intake is associated with better survival in ovarian cancer. <i>Cancer</i> , 2013, 119, 555-562.	4.1	139
43	Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 407-415.	3.3	11
44	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2013, 73, 7222-7231.	0.9	153
45	HtrA1 Peptidase. , 2013, , 2577-2584.		1
46	HtrA3 Peptidase. , 2013, , 2584-2590.		0
47	Nanoceria: A Rare-Earth Nanoparticle as a Novel Anti-Angiogenic Therapeutic Agent in Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e54578.	2.5	206
48	Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2013, 3, 251.	2.8	84
49	Metformin is synthetically lethal with glucose withdrawal in cancer cells. <i>Cell Cycle</i> , 2012, 11, 2779-2779.	2.6	0
50	Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo. <i>Breast Cancer Research</i> , 2012, 14, R43.	5.0	15
51	Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines. <i>Molecular Carcinogenesis</i> , 2012, 51, 565-575.	2.7	10
52	HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation. <i>International Journal of Cancer</i> , 2012, 130, 1029-1035.	5.1	43
53	Expression and Functional Significance of HtrA1 Loss in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 427-436.	7.0	39
54	Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In Vivo. <i>Neoplasia</i> , 2011, 13, 483-488.	5.3	273

#	ARTICLE	IF	CITATIONS
55	Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. <i>Modern Pathology</i> , 2011, 24, 277-287.	5.5	30
56	HSulf-1 Modulates FGF2- and Hypoxia-Mediated Migration and Invasion of Breast Cancer Cells. <i>Cancer Research</i> , 2011, 71, 2152-2161.	0.9	49
57	Methylation Induced Gene Silencing of HtrA3 in Smoking-Related Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 398-409.	7.0	47
58	High Temperature Requirement A3 (HtrA3) Promotes Etoposide- and Cisplatin-induced Cytotoxicity in Lung Cancer Cell Lines. <i>Journal of Biological Chemistry</i> , 2010, 285, 12011-12027.	3.4	45
59	The Serine Protease HtrA1 Specifically Interacts and Degrades the Tuberous Sclerosis Complex 2 Protein. <i>Molecular Cancer Research</i> , 2010, 8, 1248-1260.	3.4	41
60	Downregulation of HtrA1 Promotes Resistance to Anoikis and Peritoneal Dissemination of Ovarian Cancer Cells. <i>Cancer Research</i> , 2010, 70, 3109-3118.	0.9	143
61	Serine Protease HtrA1 Associates with Microtubules and Inhibits Cell Migration. <i>Molecular and Cellular Biology</i> , 2009, 29, 4177-4187.	2.3	99
62	Regulation of HSulf-1 Expression by Variant Hepatic Nuclear Factor 1 in Ovarian Cancer. <i>Cancer Research</i> , 2009, 69, 4843-4850.	0.9	40
63	Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 253-263.	2.6	36
64	Elevated expression of serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 557.e1-557.e10.	1.3	38
65	Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2007, 282, 14413-14420.	3.4	71
66	SULF1 Inhibits Tumor Growth and Potentiates the Effects of Histone Deacetylase Inhibitors in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2006, 130, 2130-2144.	1.3	64
67	HSulf-1 Inhibits Angiogenesis and Tumorigenesis In vivo. <i>Cancer Research</i> , 2006, 66, 6025-6032.	0.9	131
68	A Variant of the <i>HTRA1</i> Gene Increases Susceptibility to Age-Related Macular Degeneration. <i>Science</i> , 2006, 314, 992-993.	12.6	735
69	Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. <i>Journal of Clinical Investigation</i> , 2006, 116, 1994-2004.	8.2	130
70	Implications of the serine protease HtrA1 in amyloid precursor protein processing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 6021-6026.	7.1	188
71	HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. <i>Oncogene</i> , 2004, 23, 1439-1447.	5.9	132
72	A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. <i>Oncogene</i> , 2004, 23, 1636-1644.	5.9	157

#	ARTICLE	IF	CITATIONS
73	Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer. Journal of Biological Chemistry, 2003, 278, 23107-23117.	3.4	215
74	Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Research, 2002, 62, 262-70.	0.9	76
75	A novel region of deletion on chromosome 6q23.3 spanning less than 500Kb in high grade invasive epithelial ovarian cancer. Oncogene, 1999, 18, 3913-3918.	5.9	32
76	Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. , 1999, 24, 48-55.		31
77	Emerging Drug Therapies for Mesothelioma. , 0, , .		1